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Context: 
The experimental paradigm of acute caloric restriction followed by refeeding can be used to 
study the homeostatic mechanisms that regulate energy homeostasis, which are relevant to 
understanding the adaptive response to weight loss.  
Objective: 
Metabolomics, the measurement of hundreds of small molecule metabolites, their precursors, 
derivatives, and degradation products, has emerged as a useful tool for the study of physiology 
and disease and was used here to study the metabolic response to acute caloric restriction.  
Participants, Design and Setting: 
We used four ultra high performance liquid chromatography-tandem mass spectrometry methods 
to characterize changes in carbohydrates, lipids, amino acids and steroids in eight normal weight 
men at baseline, after 48 hours of caloric restriction (CR; 10% of energy requirements) and after 
48 hours of ad libitum refeeding in a tightly-controlled environment.  
Results: 
We identified a distinct metabolomic signature associated with acute CR characterized by the 
expected switch from carbohydrate to fat utilization with increased lipolysis and beta-fatty acid 
oxidation. We found an increase in omega-fatty acid oxidation and levels of endocannabinoids 
which are known to promote food intake. These changes were reversed with refeeding. Several 
plasmalogen phosphatidylethanolamines (endogenous anti-oxidants) significantly decreased with 
CR (all p≤0.0007). Additionally, acute CR was associated with an increase in the branched chain 
amino acids (all p≤1.4x10-7) and dehydroepiandrosterone sulfate (p=0.0006). 
Conclusions: 
We identified a distinct metabolomic signature associated with acute CR. Further studies are 
needed to characterise the mechanisms that mediate these changes and their potential 
contribution to the adaptive response to dietary restriction. 
We conducted a metabolomic analysis of 770 small molecules in eight healthy lean men and identified a 
distinct metabolomic signature associated with acute caloric restriction. 
Introduction 
The adipocyte-derived hormone leptin circulates at concentrations proportional to fat mass in 
weight-stable humans and is a pivotal regulator of energy homeostasis [1-3]. Most individuals 
maintain a relatively stable body weight over long periods of time despite day-to-day 
fluctuations in the number of calories consumed and the amount of physical activity undertaken. 
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Loss of fat mass leads to a fall in circulating leptin concentrations triggering changes in energy 
intake, energy expenditure and neuroendocrine function that restore energy homeostasis, 
resulting in rebound weight gain - the phenomenon popularly known as yo-yo dieting. 
Rosenbaum and Leibel have shown that leptin administration in short-term human studies can 
reverse many of the consequences of weight loss (a state of partial leptin deficiency) [4, 5]. 
However, recombinant leptin/leptin mimetics are not currently available for this purpose. The 
identification of additional markers of the homeostatic response to weight loss could inform 
therapeutic strategies to prevent weight regain and aid weight maintenance.  
In seminal studies in mice, Ahima and Flier showed that as well as being a marker of fat 
mass, leptin acts as a signal of nutrient availability; acute caloric restriction/starvation (without 
loss of fat mass), leads to a rapid fall in circulating leptin concentration, hyperphagia, reduced 
energy expenditure and hypogonadism [6], features which mimic genetic leptin deficiency in 
rodents and humans [7, 8] and can be normalized by leptin administration [6, 9]. Acute caloric 
restriction (CR) in humans can therefore be used as a model for investigating leptin-mediated 
homeostatic responses without the potential confounding effects of weight loss. 
The metabolomic profile at a given timepoint represents the cumulative effects of the diet, 
genome, transcriptome, proteome and gut microbiome–host interaction on small molecule 
metabolites whose concentrations change rapidly [10]. By measuring the metabolome in the 
same individuals before and after a precise perturbation, our aim was to identify the metabolites 
which change significantly with acute CR and refeeding. We assessed the short-term adaptation 
to CR to avoid confounding with metabolic changes related to weight loss. 
We performed a carefully-controlled experimental study to directly examine the effects of 
acute CR in eight normal weight young men housed in a Clinical Research Facility where diet, 
fluid intake, timing of meals and sleep were precisely controlled and monitored (Supplementary 
Table 1). Fasting blood samples were obtained at three timepoints: baseline (after 24hr feeding 
to normal energy requirements); after 48 hours of CR to 10% of their normal energy 
requirements (mean 226 ± SEM 5 kcal/day); after 48 hours of ad libitum refeeding (RF) to allow 
for energy homeostasis to be reset. Critically, the proportion of macronutrients received during 
CR was the same as on the baseline day (50% carbohydrate, 30% fat, 20% protein). In a previous 
study, we have shown that this experimental manipulation is sufficient to significantly alter 
physiological parameters including autonomic function, neuroendocrine hormone secretion and 
the sleep/wake cycle [11]. Here, in addition to measuring circulating hormones and peptides 
predicted to be altered by nutritional status (e.g. leptin, insulin, glucagon, thyroid hormones), we 
used a high throughput metabolomics assay employing four independent ultra high performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods to measure 770 
small molecule metabolites involved in carbohydrate, fat, protein and steroid metabolism.  
Material and Methods 
Experimental design of study 
The study was approved by the Cambridge local research ethics committee and was conducted in 
accordance with the principles of the Declaration of Helsinki. Written informed consent was 
received from each participant prior to inclusion in the study. We recruited eight normal weight 
healthy men using the following inclusion criteria: normal glucose tolerance measured by a 75-
gram oral glucose tolerance test, no evidence of renal, liver or thyroid disease, average alcohol 
intake <2 units/day, not participating in an organized exercise program, not treated with 
anorectic agents or medications known to affect carbohydrate and/or lipid metabolism, or blood 
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pressure. Shift workers were excluded from the study; all participants had a normal sleep/wake 
pattern as determined by polysomnography at screening. Weight and height were measured 
barefoot in light clothing and body mass index calculated (weight in kg/height in meters 
squared). Baseline characteristics are provided in Supplementary Table 1. 
Participants were resident on the NIHR-Wellcome Trust Clinical Research Facility, 
Addenbrooke’s Hospital, Cambridge, UK, for the duration of the study under direct observation 
throughout. At baseline, volunteers consumed a balanced diet (50% carbohydrate, 30% fat, 20% 
protein) matching their daily energy requirement calculated by the basal metabolic rate 
multiplied by a physical activity level of 1.25 using the Schofield equation [12]. To manipulate 
energy balance, baseline measurements were followed by CR to 10% of normal energy 
requirement (mean 226 ± SEM 5 kcal/day) for two days. After CR, participants were offered 
three substantial ad libitum buffet meals per day (20 MJ = 4777 kcal) and additional snacks (16 
MJ = 3821 kcal) between meals for two days. They were invited to eat freely until comfortably 
full; food consumption was covertly measured. Fluid intake was fixed for all participants; no 
coffee/tea/alcohol was permitted. All meals were given at the same time each day. Timing of 
“lights out” and waking were controlled. We collected fasting serum and plasma samples at 0800 
a.m. at baseline, after CR, and RF. 
Biochemical assays 
Plasma glucose, insulin, glucagon, leptin, serum lipids, thyrotropin, free thyroxine (T4), and free 
tri-iodothyronine (T3). Testosterone and dehydroepiandrosterone sulfate (DHEAS) were 
measured with a DiaSorin Liaison XL analyzer (Saluggia, Italy), and 3-hydroxybutyrate using 
the Stanbio colorimetric kit (Boerne, TX). Blood samples were collected in the fasting state at 
08:00 a.m. 
Metabolomic platform 
The non-targeted metabolomic analysis was performed at Metabolon, Inc. (Durham, North 
Carolina, USA). All serum samples were stored at –80°C until processed. The detailed 
descriptions of the platform, including sample processing, instrument configuration, data 
acquisition, and metabolite identification and quantitation, were published previously [10] with 
the exception that four independent UPLC-MS/MS methods were used. The samples were 
extracted with methanol and the supernatants were divided into five equal fractions for analysis 
by UPLC-MS/MS: 1) reverse phase (RP) UPLC-MS/MS method with positive ion mode 
electrospray ionization (ESI), optimized for more hydrophilic compounds. In this method, the 
extract was gradient eluted from a C18 column (Waters UPLC BEH C18-2.1x100 mm, 1.7 µm) 
using water and methanol, containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic 
acid (FA); 2) RP/UPLC-MS/MS method with positive ion mode ESI, optimized for more 
hydrophobic compounds. In this method, the extract was gradient eluted from the same afore 
mentioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and was 
operated at an overall higher organic content; 3) RP/UPLC-MS/MS method with negative ion 
mode ESI. In this method, the extract was gradient eluted from the column using methanol and 
water, however with 6.5mM Ammonium Bicarbonate at pH 8; 4) hydrophilic interaction liquid 
chromatography (HILIC)/UPLC-MS/MS with negative ion mode ESI. In this method, the extract 
was gradient eluted using water and acetonitrile with 10 mM ammonium formate, pH 10.8; and 
5) reserved for backup. For UPLC-MS/MS, all methods utilized a Waters ACQUITY ultra-
performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high 
resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) 
source and Orbitrap mass analyzer operated at 35,000 mass resolution. All the methods 
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alternated between full scan MS and data-dependent MSn scans using dynamic exclusion. The 
scan range varied slighted between methods but generally covered 70-1000 m/z. 
The structure of metabolites were identified by automated comparison of the ion features in 
the experimental samples to a reference library of chemical standard entries that included 
retention time, molecular weight (m/z), preferred adducts, and in-source fragments as well as 
associated MS spectra and curated by visual inspection for quality control using software 
developed at Metabolon [13-15]. 
Statistical analyses 
Statistical analyses of biochemistry results.  
Log-transformed values were analyzed using analysis of variance (ANOVA) with repeated 
measures to test for within-subject changes across the three study conditions (baseline, CR, 
refeeding). The within-subjects p-value was adjusted using the Greenhouse-Geisser correction 
factor for lack of sphericity. Pairwise comparisons of the three study conditions were performed 
by two-sided Student’s t-test when appropriate. A p-value of 0.05 was considered significant 
after Bonferroni correction for multiple comparisons. 
Statistical analyses of metabolite semi-quantitative levels.  
Following scaling of the ion count (so that the median equals 1), imputation of any missing 
values with the minimum observed value for each metabolite and log transformation, ANOVA 
contrasts and Welch’s matched-pair t-tests were used to identify biochemicals that differed 
significantly between experimental groups. Multiple comparisons were accounted for with the 
false discovery (FDR) rate method [16]. An estimate of the false discovery rate (q-value) was 
calculated to take into account the multiple comparisons that normally occur in metabolomic-
based studies. A low q-value (q<0.10) is an indication of high confidence in a result. While a 
higher q-value indicates diminished confidence, it does not necessarily rule out the significance 
of a result. Principal components analysis (PCA) and hierarchical clustering of scaled, imputed 
and log-transformed metabolite levels are detailed in the Supplementary Methods. Statistical 
analyses were performed using JMP (SAS, http://www.jmp.com) and R software (http://cran.r-
project.org/). 
Results 
A Metabolomic Signature of Caloric Restriction 
Acute CR was associated with a significant fall in circulating fasting leptin, insulin and glucose 
concentrations and an increase in glucagon levels (Table 1). We noted a decrease in free T3 but 
no significant change in thyrotropin or free T4 in response to acute CR as seen in some previous 
studies [17, 18]. Most parameters returned to baseline values with refeeding whilst others 
(insulin, glucagon) were sensitive to the overconsumption of calories on ad libitum refeeding and 
exceeded baseline values (Table 1). 
We explored the metabolomic profile for each participant at baseline, CR and in the refed 
state by employing multivariate statistical analyses to analyse state-dependent changes. PCA was 
conducted on log-transformed metabolite levels to identify whether aggregated values of specific 
components could account for a proportion of the variability between baseline, CR and 
refeeding. We found that the PCA of the metabolome completely distinguished the three states 
revealing a characteristic metabolomic signature associated with CR (Figure 1A). Whilst within 
a state, there was variability between participants (presumably due to genetic/biological factors), 
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the magnitude and direction of effect of CR and refeeding was comparable for all participants 
(Supplementary Figure 1). 
A substantial proportion of the entire metabolome exhibited a dynamic response to CR and 
refeeding (Figure 1B). We used hierarchical clustering to identify large-scale differences in 
metabolite categories for each individual in each state. The resulting heatmap revealed that CR 
induced a number of changes in lipid and carbohydrate utilization; some of which were reversed 
upon refeeding (Figure 1C). Further discussion is focused on metabolites that constitute this 
dynamic metabolomic signature. The complete dataset is presented in Supplementary Table 2 
an associated interactive webpage is available (link active on publication). 
Carbohydrate utilization: glycolysis and the TCA cycle 
Classically, glycolysis converts glucose to pyruvate, which, under aerobic conditions, is 
converted into acetyl-CoA, the entry point into the tricarboxylic acid (TCA) cycle (Figure 2A). 
As expected, CR was associated with a decrease in glucose (fold change 0.84, p=5.9 x 10-5) and 
pyruvate (fold change 0.32, p=9.0 x 10-4) which were restored by refeeding (fold change 1.14 
and 10.8, p=8.0 x 10-4 and 1.2 x 10-7, respectively) (Figure 2A). Citrate and aconitate were 
significantly elevated with CR, there was no change in isocitrate or alpha-ketoglutarate, but a 
significant decrease in succinylcarnitine, an intermediate arising reversibly from succinyl-CoA 
(Figure 2A). N-acetyl derivatives of the glucogenic amino acids glycine, serine and alanine 
increased with CR and decreased with refeeding (Figure 2B). In contrast, glutamate and its 
product N-acetylglutamate decreased with CR (Figure 2B). These changes reversed upon 
refeeding and collectively are consistent with an increase in metabolite flux through the TCA 
cycle in response to CR. 
While some N-acetylated amino acid derivatives followed the same pattern across baseline-
CR-RF conditions as their corresponding amino acids (e.g. Glutamate, Serine), others did not 
(e.g. Glycine, Alanine, Figure 2B). The reasons for the differential effects of CR on N-
acetylation of gluconeogenic amino acids need further investigation. 
Lipolysis and Fatty acid oxidation 
CR was characterized by lipolysis of triglycerides generating increased levels of glycerol (2.43 
fold, p=0.0003), decreased monoacylglycerols and an increase of all long and most medium 
chain fatty acids detected (Figure 3A-C). During CR, we found a significant increase in long-
chain acylcarnitines which shuttle fatty acids into mitochondria (Figure 3D). Consequently, the 
ketone bodies acetoacetate and 3-hydroxybutyrate, final products of the fatty acid β-oxidation 
pathway, were markedly increased with CR (p=1.6 x 10-11 and p=2.0 x 10-11, respectively) and 
decreased with RF (p=4.9 x 10-13 and 1.6 x 10-12, respectively) (Figure 3E). Serum levels of 
ketone bodies were measured in routine laboratory tests for comparison; 3-hydroxybutyrate 
increased 17.3 fold (Table 1).  
Additionally, 3-hydroxy fatty acids were increased in keeping with increased lipolysis and 
fatty acid β-oxidation (Figure 3F). Furthermore, fatty acid dicarboxylates, in particular 
dodecanedioate and tetradecanedioate, which increased 7.7-fold on CR, are generated through 
the ω-oxidation pathway (Figure 3F). Whilst this pathway has rarely been studied in humans, 
our study suggests that activation of ω-oxidation may occur when β-oxidation becomes 
overwhelmed as it may in CR. Taken together, CR resulted in increased reliance on fatty acid 
(rather than carbohydrate) metabolism to fuel energy production. Refeeding led to a decreased 
reliance on fatty acid oxidation to meet energetic needs and stimulation of lipogenesis (Figures 
3B-F). 
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Phospholipids and endocannabinoids 
Whilst triglycerides represent the major source of stored lipid, phospholipids are the major 
constituents of plasma membrane lipids and eicosanoids such as prostaglandins, leukotrienes and 
thromboxanes. We found that most glycerophospholipids and their product lysolipids were 
decreased in CR and increased upon refeeding (Figure 4A-C). Plasmalogens are a subclass of 
glycerophospholipids that serve as endogenous anti-oxidants, protecting membrane lipids and 
lipoprotein particles from excessive oxidation by scavenging reactive oxygen species via the 
vinyl ether moiety [19, 20]. Interestingly, the plasmalogen phosphatidylethanolamines (PPEs), 
but not the plasmalogen phosphatidylcholines (PPCs), decreased on CR and increased with 
refeeding (Figure 4B).  
Sphingolipids play a role in the formation of membrane lipid rafts, are components of plasma 
lipoprotein associated particles and act as ligands for specific cell-surface receptors. In our study, 
the most abundant sphingolipids, the sphingomyelins, increased with CR; this pattern was 
reversed in the refed state (Figure 4D). Sphingosine, sphingosine-1-phosphate (S1P) and 
ceramides are interconvertible sphingolipid metabolites; many studies have shown that their 
relative levels regulate cell fate [21, 22]. Levels of sphingosine (generally associated with growth 
arrest and cell death) decreased in CR (0.52 fold, p=0.03) whilst there was no change in S1P 
which is involved in cell growth and survival. 
Another group of lipid signaling molecules, the endocannabinoids, modulate energy intake 
and expenditure by acting on central neural pathways expressing the cannibinoid 1 receptor, a 
target of the weight-loss agent rimonabant [23]. Whilst there was no change in 2-arachidonoyl 
glycerol (2-AG), the most abundant endogenous ligand of cannabinoid receptors which has a 
very short half-life (Supplementary Table 2), all other detected endocannabinoids increased in 
CR then decreased upon refeeding (Figure 4E). These findings are consistent with experimental 
evidence in animals where a key role for endogeneous endocannabinoids is to stimulate food 
intake [24]. 
Amino acids and their derivatives 
Several amino acids and their metabolites (in particular Tryptophan and its derivatives) 
decreased in CR, then increased with refeeding (Figure 1C; Supplementary Table 2); these 
changes may in part reflect reduced dietary intake. In contrast, the three branched chain amino 
acids (BCAAs), leucine, isoleucine and valine significantly increased upon CR (all p≤1.4 x 10-7, 
Figure 5A). BCAAs are degraded by the branched-chain alpha-keto acid dehydrogenase
complex into acyl-CoA derivatives, which are converted into acetyl-CoA or succinyl-CoA that 
enter the TCA cycle. We observed increased levels of many BCAA catabolites consistent with 
accelerated BCAA catabolism under CR which reversed upon refeeding (Supplementary 
Figure 2). 
Steroid Metabolism 
In contrast to cortisol which changes minimally with age, circulating concentrations of the 
adrenal steroid hormone DHEAS are high during early adulthood then decline markedly with age 
[25]. Some, but not all, studies in primates and humans [26] have suggested that chronic CR may 
affect DHEAS levels. In this study, 48 hours of CR was associated with an increase in DHEAS 
and the steroid hormones pregnenolone and androsterone; values returned to baseline levels on 
refeeding (Figure 5B and Supplementary Figure 3). Cortisol levels did not change 
significantly during the study (Supplementary Table 2). 
Discussion 
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Using an experimental design in which we stabilized dietary intake across participants for 24 
hours before an observed period of acute CR, followed by ad libitum refeeding to restore energy 
homeostasis, we identified a characteristic metabolomic signature associated with acute CR. 
Some of our findings align with previous studies that have measured targeted sets of metabolites 
in response to an overnight/prolonged fast [27, 28]. Whilst changes in glycolysis and markers of 
fatty acid β-oxidation were predicted, our study shows that ω-oxidation (generally regarded as a 
minor fatty acid oxidation pathway in humans) may be activated in response to acute CR in 
healthy individuals. ω-oxidation is utilized as part of the compensation for defective beta or 
alpha-fatty acid oxidation in rare genetic disorders such as Refsum’s disease and X-linked 
adrenal leukodystrophy [29].  
We saw consistent class-wide changes in several lipid species (phospholipids, sphingolipids 
and endocannibinoids) which may reflect the mobilisation of fatty acids for energetic purposes. 
In keeping with this hypothesis, CR/RF induced changes in fatty acids correlated with changes in 
their respective fatty acyl carnitines (Supplementary Figure 4). Additionally, we observed a 
negative correlation between the change in fatty acid levels and the change in 
lysophosphatidylcholines with CR (Supplementary Figure 5), an effect that may be mediated 
by NTE neuropathy target esterase)-related esterase, an enzyme which has lysophospholipase 
activity, is expressed in adipose tissue and skeletal muscle, and is upregulated upon fasting [30]. 
By focussing on the 27 long chain fatty acids and polyunsaturated fatty acids examined in 
this study (Figure 3C), we observed that palmitoleate (16:1), a major constituent of the 
glycerides in human adipose tissue that has been associated with increased insulin sensitivity 
[31], exhibited a highly significant change with CR (3.61-fold, p=1.9 x 10-5). In contrast, 
arachidonate, a major omega-6 fatty acid and precursor of lipid-derived mediators of 
inflammation (leukotrienes and thromboxanes) changed least in response to CR (Figure 3C). 
Thus, whilst the whole scale changes in fatty acids we observed during CR represent the 
activation of fatty acid oxidation to supply energetic needs, specific changes in fatty acids may 
predispose to increased insulin sensitivity and reduced cellular inflammation, findings which 
have potential relevance to protection from aging [32, 33] and require further exploration. 
In this study, we identified a series of metabolite changes associated with acute CR without 
weight loss. The changes in carbohydrate, lipid and amino acid metabolism that we observed are 
characteristic of the counter-regulatory response that acts to defend against starvation and restore 
energy homeostasis. Whilst this degree of CR is seldom experienced by most people, short-term 
CR for weight loss engages the same physiological and biochemical mechanisms. The activation 
of these mechanisms, whose function is to restore energy balance, underpins weight regain, the 
phenomenon popularly known as yo-yo dieting. The application of metabolomics analyses to 
carefully controlled studies of weight loss and the comparison with the dataset reported here, 
may reveal novel biomarkers that predict the degree of weight loss/regain. 
Experimental studies in animal models have consistently shown that CR, typically 40-60% of 
energy requirements, can extend lifespan by up to 50% compared to ad libitum fed animals [34-
36]. Our study permits comparison with a large body of research into the effects of CR in lower 
organisms, although there are challenges in comparing data across species and from serum rather 
than cells/tissues [37, 38]. One particularly interesting convergence is the finding that some 
phosphatidylethanolamines (PEs), lipids that are known to affect cell survival and the lifespan of 
yeast and flies [39], decreased with CR and increased with RF. 
In conclusion, we have shown that analysis of the metabolome in a carefully conducted 
clinical study can provide insights into the mechanisms underpinning physiological processes 
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such as the response to acute CR in humans. With replication, these studies have the potential to 
provide valuable insights into the mechanisms underlying the effects of caloric restriction which 
may inform new therapeutic opportunities for weight maintenance.  
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Figure 1. Metabolomic signature of caloric restriction. Seven hundred and seventy 
metabolites were measured in eight subjects at three timepoints: baseline (gray), after caloric 
restriction (black) and upon refeeding (white). Panel A shows the Principal Component Analysis; 
Principal component 1 (PC1) captured 38.5% of the variance of the dataset and discriminated 
well between the three study conditions, while component 2 (PC2) covered 9.4% of the variance. 
Changes in metabolite categories are shown in Panels B and C: Amino acids (dark orange), 
Peptides (light orange), Carbohydrates (red), Energy and the TCA (tricarboxylic acid) cycle 
(pink), Lipids (dark green), Nucleotides (light green), Cofactors and vitamins (dark blue), and 
Xenobiotics (light blue). Panel B shows a Volcano plot of the statistical significance as indicated 
by P values (y-axis) associated with fold change in each metabolite (x-axis); baseline to caloric 
restriction (filled circles); caloric restriction to refeeding (open circles). A large percentage of 
metabolites significantly increased (38%; n=295) or decreased (39%; n=300) upon caloric 
restriction. Panel C shows a heatmap derived from hierarchical clustering of the metabolomic 
data. Clustering was performed using complete linkage and Euclidean distance, where each 
sample is a vector with all of the metabolite values. The color scale correlates with relative 
metabolite abundance across the samples: the black indicates median value, red an elevation 
above the median, and green a decrease below the median. 
Figure 2. Glycolysis and gluconeogenesis. Panel A shows statistically significant increases 
(red) and decreases (green) in metabolites involved in glycolysis and the TCA (tricarboxylic 
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acid) cycle with caloric restriction (CR, black bars) and upon refeeding (RF, white bars). Fold 
changes in glucose, pyruvate and TCA cycle components are shown (y-axis). Some metabolites 
were not measured in this assay (gray). Statistical significance is presented as follows: + for p-
values between 0.001 and 0.05; * for p-values ≤0.001; ** for p-values ≤0.001 and q-values 
≤0.001. Panel B shows fold changes in glucogenic amino acids and their N-acetyl-derivatives 
during the study. Plots show means ± SEM of the eight subjects at baseline (BL, gray), CR 
(black) and RF (white).  
Figure 3. Fatty acid oxidation and lipolysis. Panel A shows metabolites involved in lipolysis 
and fatty acid oxidation that significantly increased (red) or decreased (green) with caloric 
restriction (CR). Some metabolites were not measured in this assay (gray). Panel B-D show fold 
changes in monoacylglycerols (MAG; B), medium and long-chain fatty acids (C), and 
acylcarnitines (CAR; D) with CR (black) and refeeding (RF, white). Lipid species are annotated 
using the following convention: lipid class ([number of carbon atoms]:[number of double bonds], 
[position of double bond(s) if known]). In addition for MAG, sn1 or sn2 indicate the 
esterification position in the glycerol backbone which links the acyl group. Some fatty acids are 
also designated by abbreviations, such as AA (arachidonic acid), DHA (docosahexaenoate), DPA 
(docosapentaenoate), and EPA (eicosapentaenoate). Panel E shows fold changes in ketone bodies 
between baseline (BL), CR and RF; means ± SEM are shown. Panel F shows fold changes with 
CR (black) and RF (white) in other lipid species involved in fatty acid oxidation. Statistical 
significance is presented as follows: + for p-values between 0.001 and 0.05; * for p-values 
≤0.001; ** for p-values ≤0.001 and q-values ≤0.001. 
Figure 4. Phospholipids and other lipid mediators. Fold changes in phospholipids and other 
lipid mediators with caloric restriction (CR, black) and refeeding (RF, white): 
Glycerophospholipids (Panel A), plasmalogens (B), lysophospholipids (C), sphingomyelins (D). 
Lipid species are abbreviated as such: LPC, lysophosphatidylcholine; LPE, 
lysophosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PPC, 
plasmalogen phosphatidylcholine; PPE, plasmalogen phosphatidylethanolamine; SM, 
sphingomyelin. The acyl group(s) are specified using the following convention: [number of 
carbon atoms]:[number of double bonds], [position of double bond(s) if known]; or the total 
numbers if unknown. In addition for LPC and LPE, sn1 or sn2 indicate the esterification position 
in the glycerol backbone which links the acyl group. PC(18:0/20:3)a and PC(18:0/20:3)b are 
structurally similar but differ by the position of the double bonds. The precise structure of 
PC(38:5)a and PC(38:5)b could not be specified. Statistical significance is presented as follows: + 
for p-values between 0.001 and 0.05; * for p-values ≤0.001; ** for p-values ≤0.001 and q-values 
≤0.001. Panel E shows fold changes in endocannabinoids between baseline (BL), CR and RF; 
means ± SEM are shown. 
Figure 5. Amino acids and Steroid Hormones. Panel A shows fold changes in the branched 
chain amino acids (BCAA) valine, isoleucine and leucine between baseline (BL), caloric 
restriction (CR) and refeeding (RF); means ± SEM are shown. Steps in BCAA catabolism are 
shown; metabolites that significantly increased (red) or decreased (green) with CR are indicated. 
Some metabolites were not measured in this assay (gray). Panel B shows fold changes in a subset 
of steroid hormones between conditions; means ± SEM are shown. 
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Table 1. Changes in fasting biochemistry in caloric restriction and upon refeeding 
Mean (SEM) Baseline Caloric 
restriction 
Refeeding P values for overall comparison 
Overall BL-CR CR-RF BL-RF 
Caloric intake, kcal/day 2255 (53) 226 (5) 4552 (324) <0.0001 <0.001 <0.001 <0.001 
Glucose metabolism a        
Glucose, mmol/l 4.74 (0.12) 3.48 (0.08) 4.70 (0.11) <0.0001 <0.001 <0.001 1.00 
Insulin, pmol/l  44.6 (7.7) 14.6 (2.6) 87.6 (14.2) <0.0001 <0.001 <0.001 <0.001 
Glucagon, pg/ml 24.8 (2.7) 74.7 (11.6) 38.2 (4.2) 0.0001 <0.001 <0.001 0.01 
3-OH butyrate, µmol/l 101.8 (7.8) 1763 (258) 93.7 (7.4) <0.0001 <0.001 <0.001 1.00 
Leptin, ng/ml 3.26 (0.81) 0.66 (0.19) 4.55 (1.34) <0.0001 <0.001 <0.001 0.22 
Lipid metabolism b        
Total cholesterol, mmol/l 4.11 (0.34) 4.30 (0.29) 3.73 (0.27) 0.0009 0.18 <0.001 0.006 
Triglycerides, mmol/l 1.31 (0.11) 1.24 (0.10) 1.52 (0.14) 0.10    
Thyroid function c        
TSH, mU/l 1.34 (0.18) 1.14 (0.19) 2.00 (0.29) 0.006 0.20 0.001 0.04 
Free T4, pmol/l 13.93 (0.35) 14.80 (0.51) 14.94 (0.47) 0.03 0.07 1.00 0.03 
Free T3, pmol/l  5.02 (0.19) 3.92 (0.17) 4.65 (0.28) 0.001 <0.001 0.002 0.12 
Steroids c        
Testosterone, nmol/l 18.51 (2.10) 17.05 (2.52) 15.27 (2.12) 0.10    
DHEAS, µg/dl 312.2 (43.8) 347.1 (39.9) 298.6 (49.7) 0.10    
Abbreviations: 3-OH butyrate, 3-hydroxybutyrate; BL, baseline; CR, caloric restriction; DHEAS, 
dehydroepiandrosterone sulfate; RF, refeeding; T3, tri-iodothyronine; T4, thyroxine; TSH, thyroid-stimulating 
hormone. 
Footnotes: Data are presented as mean values and standard error of the mean (SEM). We tested the correlation of 
biochemistry assay concentrations with levels measured by metabolomics: the Pearson correlation ranged between ρ 
= 0.87 and ρ = 0.95 (for glucose, 3-OH butyrate and DHEAS), but was lower for cholesterol (ρ = 0.70; our 
metabolomics platform measures free cholesterol whereas the standard clinical assay measures total cholesterol) and 
free T4 (ρ = 0.50). a To convert glucose values to milligrams per deciliter, multiply by 18. To convert 3-OH butyrate 
values to milligrams per deciliter, divide by 96.09. Reference ranges for insulin: 0-60 pmol/l; 3-OH butyrate: 20-270 
µmol/l. b To convert lipid values to milligrams per deciliter, multiply by 38.7 for total cholesterol and 88.5 for 
triglycerides. c Reference ranges for TSH: 0.35-5.5 mU/l; free T4: 10.0-19.8 pmol/l; free T3: 3.5-6.5 pmol/l; 
testosterone: 8.0-29.0 nmol/l, DHEAS: 161.2-561.6 µg/dl. 
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